Drug Approval | August 30, 2024
Natco Pharma announces submission of TABRECTA to USFDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
e brings over 27+ years of rich pharmaceutical experience
Nor UDCA is likely to be a first-in-class treatment option for NAFLD in India
This product will be manufactured by Indoco at its manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa in India
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Morepen Labs successfully raised Rs. 200 Crore through QIP
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Subscribe To Our Newsletter & Stay Updated
